Prim-O-glucosylcimifugin is a natural product isolated and purified from the root of Saposhnikovia divaricata (Turcz.) Schischk., which can inhibit the proliferation of SMC(smooth muscle cell) stimulated by TNF-alpha, increase the proportion of G0/G1 phase.
Prim-O-glucosylcimifugin/升麻甙 细胞实验
Cell Line
Concentration
Treated Time
Description
References
B16-F10 cells
50 μM and 100 μM
48 hours
To evaluate the effect of POG on apoptosis and proliferation of B16-F10 cells. The results showed that POG exhibited no cytotoxic effect on B16-F10 cells.
J Immunother Cancer. 2019 Aug 28;7(1):231.
CD8 T-lymphocytes
50 μM and 100 μM
48 hours
To evaluate the effect of POG on apoptosis and proliferation of CD8 T-lymphocytes. The results showed that POG exhibited no cytotoxic effect on CD8 T-lymphocytes and did not affect their proliferation.
J Immunother Cancer. 2019 Aug 28;7(1):231.
PMN-MDSCs
50 μM and 100 μM
48 hours
To evaluate the effect of POG on apoptosis and proliferation of PMN-MDSCs. The results showed that POG exhibited no cytotoxic effect on PMN-MDSCs but could specifically inhibit the proliferation of PMN-MDSCs.
J Immunother Cancer. 2019 Aug 28;7(1):231.
Human tendon stem/progenitor cells (hTSPCs)
20 μmol·L−1
once every 2 days for 7 days
POG treatment enhanced colony formation and proliferative capacity of hTSPCs and reduced senescence markers
Bone Res. 2023 Oct 23;11(1):54.
Rat tendon stem/progenitor cells (rTSPCs)
20 μmol·L−1
long-term passage from P3 to P12
POG treatment significantly enhanced self-renewal and proliferative capacities of rTSPCs, reduced senescence markers, and restored tenogenic differentiation potential
Bone Res. 2023 Oct 23;11(1):54.
RAW 264.7 mouse macrophage cells
12.5, 25, 50 μg/mL
1 hour
To evaluate the inhibitory effect of Prim-O-glucosylcimifugin on LPS-induced cytokine production. Results showed that Prim-O-glucosylcimifugin significantly inhibited the production of TNF-α, IL-1β, and IL-6, and increased the level of IL-10.
Int Immunopharmacol. 2013 Jun;16(2):139-47.
RAW264.7 cells
12.5, 25, 50 μmol/mL
24 hours
POG significantly suppressed the production of inflammatory factors (TNF-α, IL-1β, IL-6) in LPS-induced RAW264.7 cells and inhibited inflammatory responses by suppressing the phosphorylation of ERK1/2, AKT, JNK1/2, IκB-α, P38, and P65.
Front Pharmacol. 2022 May 18;13:882924.
Human SGC7901 GC cell line
100 μM
To evaluate the inhibitory effects of POG and its metabolite cimifugin on COX-2 expression, results showed that POG and cimifugin downregulated COX-2 expression
Biomol Ther (Seoul). 2016 Jul 1;24(4):418-25.
A549/DDP cells
0–10 μM
48 hours
Decreased GST activity by ∼5%, decreased GSTPi1 expression by ∼18%, decreased GSTM1 expression by ∼50%, increased intracellular platinum accumulation by ∼30%, enhanced cell apoptosis by ∼10%
Front Pharmacol. 2021 May 28;12:678126.
A549 cells
0–10 μM
48 hours
Decreased GST activity by ∼10%, decreased GSTPi1 expression by ∼33%, decreased GSTM1 expression by ∼70%, increased intracellular platinum accumulation by ∼56%, enhanced cell apoptosis by ∼10%
Front Pharmacol. 2021 May 28;12:678126.
Prim-O-glucosylcimifugin/升麻甙 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
B16-F10 melanoma model
Intraperitoneal injection
100 mg/kg/day and 200 mg/kg/day
Once daily for 14 days
To evaluate the dose-dependent effect of POG on B16-F10 tumor growth. The results showed that POG significantly inhibited tumor growth in a dose-dependent manner, and 200 mg/kg had no significant effect on the body weight of mice.
J Immunother Cancer. 2019 Aug 28;7(1):231.
Rats
Partial transection tendon injury model in 18-month-old rats
Oral
50 mg/kg body weight per day
Once daily for 2 months
Oral POG significantly improved tendon self-healing capacity in aged rats, reducing inflammation and senescence markers
Bone Res. 2023 Oct 23;11(1):54.
BALB/c male mice
LPS-induced acute lung injury model
Intraperitoneal injection
2.5, 5, 10 mg/kg
Single dose, lasting 7 hours
To evaluate the protective effect of Prim-O-glucosylcimifugin on LPS-induced acute lung injury. Results showed that Prim-O-glucosylcimifugin significantly reduced inflammatory cell infiltration, edema, and MPO activity in lung tissues, and improved histopathological changes.
Int Immunopharmacol. 2013 Jun;16(2):139-47.
C57BL/6 mice
DSS-induced ulcerative colitis model
Intraperitoneal injection
2.5, 5, 10 mg/kg
7 consecutive days
POG improved clinical scores, colonic length, and body weight in DSS-induced ulcerative colitis mice, repaired pathological damage to the intestinal mucosa, inhibited levels of inflammatory factors (IL-1β, TNF-α, IL-6), and repaired the intestinal immune barrier by upregulating the expression of tight junction proteins (Occludin, Claudin-3, ZO-1). Additionally, POG regulated the richness and structure of intestinal microbiota.
Front Pharmacol. 2022 May 18;13:882924.
Wistar rats
Formalin-induced tonic nociceptive response model and CFA-induced rat arthritis pain model
Subcutaneous injection
1, 3, 10, 30 mg/kg
Single dose or consecutive administration for 7 days
To evaluate the anti-nociceptive effects of POG in inflammatory nociception, results showed that POG dose-dependently inhibited nociceptive responses without tolerance, reduced serum TNFα, IL-1β, and IL-6 levels, and decreased spinal PGE2 and COX-2 expression
搜索
